JAK2
Driver mutation in myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, myelofibrosis). Targeted by ruxolitinib, fedratinib.
No Clinical Trials found for this biomarker.
Driver mutation in myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, myelofibrosis). Targeted by ruxolitinib, fedratinib.
No Clinical Trials found for this biomarker.